单位:[1]Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, Hubei Cancer Clinical Study Center, Wuhan, Hubei, China.[2]Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America.[3]Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.[4]Health Science Center, Hubei Minzu University, Enshi, China.[5]Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.肿瘤科华中科技大学同济医学院附属同济医院
第一作者单位:[1]Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, Hubei Cancer Clinical Study Center, Wuhan, Hubei, China.[2]Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America.
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Wang Qiao-Li,Gong Caifeng,Meng Xiang-Yu,et al.TPP1 is associated with risk of advanced precursors and cervical cancer survival[J].Plos One.2024,19(5):e0298118.doi:10.1371/journal.pone.0298118.
APA:
Wang Qiao-Li,Gong Caifeng,Meng Xiang-Yu,Fu Min,Yang Hui...&Zhou Yunfeng.(2024).TPP1 is associated with risk of advanced precursors and cervical cancer survival.Plos One,19,(5)
MLA:
Wang Qiao-Li,et al."TPP1 is associated with risk of advanced precursors and cervical cancer survival".Plos One 19..5(2024):e0298118